NO20045140L - Blandinger og fremgangsmate for transmukosal legemiddelavlevering og kryobeskyttelse - Google Patents
Blandinger og fremgangsmate for transmukosal legemiddelavlevering og kryobeskyttelseInfo
- Publication number
- NO20045140L NO20045140L NO20045140A NO20045140A NO20045140L NO 20045140 L NO20045140 L NO 20045140L NO 20045140 A NO20045140 A NO 20045140A NO 20045140 A NO20045140 A NO 20045140A NO 20045140 L NO20045140 L NO 20045140L
- Authority
- NO
- Norway
- Prior art keywords
- cryoprotection
- methods
- glycol derivative
- transmucosal delivery
- mixtures
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 238000012377 drug delivery Methods 0.000 title 1
- 150000002334 glycols Chemical class 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 210000002257 embryonic structure Anatomy 0.000 abstract 2
- 210000004877 mucosa Anatomy 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002577 cryoprotective agent Substances 0.000 abstract 1
- 239000012052 hydrophilic carrier Substances 0.000 abstract 1
- 230000003232 mucoadhesive effect Effects 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38264402P | 2002-05-23 | 2002-05-23 | |
PCT/US2003/016313 WO2003099264A1 (en) | 2002-05-23 | 2003-05-22 | Compositions and method for transmucosal drug delivery and cryoprotection |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20045140L true NO20045140L (no) | 2005-02-22 |
Family
ID=29584435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20045140A NO20045140L (no) | 2002-05-23 | 2004-11-25 | Blandinger og fremgangsmate for transmukosal legemiddelavlevering og kryobeskyttelse |
Country Status (11)
Country | Link |
---|---|
US (1) | US7939098B2 (zh) |
EP (1) | EP1509209A1 (zh) |
JP (1) | JP2005531570A (zh) |
CN (1) | CN100522245C (zh) |
AU (1) | AU2003233653B2 (zh) |
BR (1) | BR0311530A (zh) |
CA (1) | CA2486909A1 (zh) |
HK (1) | HK1081844A1 (zh) |
MX (1) | MXPA04011584A (zh) |
NO (1) | NO20045140L (zh) |
WO (1) | WO2003099264A1 (zh) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2477321A1 (en) * | 2002-02-25 | 2003-08-28 | Lyfjathroun Hf | Absorption enhancing agent |
US6855332B2 (en) * | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
EP1667619A4 (en) * | 2003-09-19 | 2007-10-10 | Drugtech Corp | PHARMACEUTICAL FEEDING SYSTEM |
US20060140990A1 (en) * | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
US20050118246A1 (en) * | 2003-10-31 | 2005-06-02 | Wong Patrick S. | Dosage forms and layered deposition processes for fabricating dosage forms |
US20050137262A1 (en) * | 2003-12-22 | 2005-06-23 | Hu Patrick C. | Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses |
ME01881B (me) | 2004-01-22 | 2014-12-20 | Univ Miami | Topijske formulacije koenzima q10 i postupci upotrebe |
DK2422789T3 (en) * | 2004-05-19 | 2018-02-26 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | INJECTABLE COMPOSITION CONTAINING SODIUM DEOXYCHOLATE |
US20060127468A1 (en) * | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
CN101005828B (zh) * | 2004-06-17 | 2012-01-11 | 维尔恩公司 | 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物 |
US20060045865A1 (en) * | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
US8110547B2 (en) * | 2005-01-12 | 2012-02-07 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
CA2605341A1 (en) * | 2005-05-09 | 2006-11-16 | Drugtech Corporation | Modified-release pharmaceutical compositions |
EP2308467A3 (en) * | 2005-06-17 | 2011-06-22 | Hospira Australia Pty Ltd | Liquid pharmaceutical formulations of docetaxel |
BRPI0615730A2 (pt) * | 2005-09-22 | 2011-05-24 | Transfert Plus Soc En Commandite | extrato de planta e uso do mesmo como agente crioprotetor |
US20070129447A1 (en) * | 2005-12-02 | 2007-06-07 | Sra Jasbir S | Method of drug therapy in treatment of cardiac arrhythmias |
AU2006332518A1 (en) * | 2006-01-05 | 2007-07-12 | Drugtech Corporation | Composition and method of use thereof |
TW200824693A (en) * | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
ES2611995T3 (es) * | 2007-01-19 | 2017-05-11 | Hananja Ehf | Métodos y composiciones para el suministro de un agente terapéutico |
US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
ES2755840T3 (es) | 2007-03-22 | 2020-04-23 | Berg Llc | Formulaciones tópicas que tienen biodisponibilidad aumentada |
KR20100136997A (ko) | 2008-04-11 | 2010-12-29 | 싸이토테크 랩스, 엘엘씨 | 암세포에서 아폽토시스를 유도하는 방법 및 용도 |
RU2519193C2 (ru) | 2008-09-12 | 2014-06-10 | Критикал Фармасьютикалс Лимитед | Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу |
CN101721404B (zh) * | 2008-10-10 | 2014-08-13 | 北京人福军威医药技术开发有限公司 | 单硝酸异山梨酯鼻腔给药组合物及其制备方法 |
WO2010062863A2 (en) | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Compositions containing satiogens and methods of use |
EP2367554A4 (en) * | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | BILIARY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF OBESITY AND DIABETES |
US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
JP5409067B2 (ja) * | 2009-03-23 | 2014-02-05 | ユニ・チャーム株式会社 | タンポン |
CA2761717A1 (en) | 2009-05-11 | 2010-11-18 | Berg Biosystems, Llc | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
US20110002966A1 (en) * | 2009-07-01 | 2011-01-06 | Alex Lovett | Vaginal Suppository System and Method |
US9014799B2 (en) * | 2009-10-08 | 2015-04-21 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including electrically-actuated permeation enhancement |
US9017310B2 (en) * | 2009-10-08 | 2015-04-28 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including microneedles |
US8882748B2 (en) * | 2009-10-08 | 2014-11-11 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including chemical permeation enhancers |
US20110152204A1 (en) * | 2009-12-18 | 2011-06-23 | Satiogen Pharmaceuticals, Inc. | Treatment of Obesity or Diabetes with Bile Acid Sequestrants |
CN101756954B (zh) * | 2010-01-05 | 2013-07-31 | 沈阳药科大学 | 硝酸异山梨酯的鼻粘膜给药制剂及其制备方法 |
CN102892412B (zh) * | 2010-03-12 | 2015-09-30 | 博格制药有限责任公司 | 辅酶Q10(CoQ10)的静脉内制剂及其使用方法 |
KR101752944B1 (ko) | 2010-05-03 | 2017-07-03 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법 |
WO2011150286A2 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals,Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
CN101856329B (zh) * | 2010-06-02 | 2012-06-06 | 上海现代药物制剂工程研究中心有限公司 | 苯甲酸利扎曲普坦口腔喷雾剂 |
AU2011200392B2 (en) * | 2011-01-31 | 2015-05-28 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device |
EP2675460A4 (en) | 2011-02-18 | 2014-07-09 | Kythera Biopharmaceuticals Inc | TREATMENT OF FAT TISSUE UNDER CHIN |
AU2012240222B2 (en) | 2011-04-04 | 2017-04-27 | Berg Llc | Methods of treating central nervous system tumors |
US8653058B2 (en) | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
US10973763B2 (en) | 2011-06-17 | 2021-04-13 | Berg Llc | Inhalable pharmaceutical compositions |
KR102051030B1 (ko) | 2011-10-28 | 2019-12-02 | 루메나 파마수티컬즈, 인코포레이티드 | 소아 담즙울체성 간 질환 치료용 담즙산 재순환 억제제 |
US9018246B2 (en) * | 2012-09-05 | 2015-04-28 | Lp Pharmaceutical (Xiamen) Co., Ltd. | Transmucosal administration of taxanes |
US9999720B2 (en) | 2012-09-27 | 2018-06-19 | Palo Alto Research Center Incorporated | Drug reconstitution and delivery device and methods |
US9005108B2 (en) | 2012-09-27 | 2015-04-14 | Palo Alto Research Center Incorporated | Multiple reservoir drug delivery device and methods |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
US9744341B2 (en) | 2013-01-15 | 2017-08-29 | Palo Alto Research Center Incorporated | Devices and methods for intraluminal retention and drug delivery |
MX2015014097A (es) | 2013-04-08 | 2016-06-07 | Berg Llc | Tratamiento de cancer empleando terapias combinadas de coenzima q10. |
IL276423B2 (en) | 2013-09-04 | 2024-05-01 | Berg Llc | Pharmaceutical preparations containing coenzyme Q10 for use in cancer treatment |
US9297083B2 (en) | 2013-12-16 | 2016-03-29 | Palo Alto Research Center Incorporated | Electrolytic gas generating devices, actuators, and methods |
CN103784941A (zh) * | 2013-12-26 | 2014-05-14 | 深圳市健元医药科技有限公司 | 一种鼻用凝胶剂组合物及其制备方法 |
US10278675B2 (en) | 2014-07-31 | 2019-05-07 | Palo Alto Research Center Incorporated | Implantable estrus detection devices, systems, and methods |
US9801660B2 (en) | 2014-07-31 | 2017-10-31 | Palo Alto Research Center Incorporated | Implantable fluid delivery devices, systems, and methods |
CN104474534A (zh) * | 2014-12-22 | 2015-04-01 | 哈德逊(天津)生物技术有限责任公司 | 白介素-18抗病毒口腔喷剂 |
KR101492572B1 (ko) | 2015-01-14 | 2015-02-11 | 주식회사 대웅제약 | 신규 약학 조성물 |
CN106333924A (zh) * | 2016-07-28 | 2017-01-18 | 顾世海 | 一种含喜树碱类化合物的药物制剂 |
WO2019182745A1 (en) * | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
CN108324688B (zh) * | 2018-04-11 | 2021-03-23 | 苏州大学 | 苯甲酸利扎曲普坦原位凝胶鼻喷剂 |
GB201808567D0 (en) * | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Pharmaceutical compositions |
US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
CN109260152A (zh) * | 2018-11-13 | 2019-01-25 | 禹州市中医院 | 一种盐酸洛美沙星滴耳液 |
CN111111480B (zh) * | 2020-01-09 | 2021-09-14 | 南京工业大学 | 一种唑来磷酸改性纳滤膜及其制备方法 |
WO2024054524A1 (en) * | 2022-09-06 | 2024-03-14 | Akande Janet Mubo | Compositions and methods for treating vaginal atrophy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60224638A (ja) * | 1984-04-23 | 1985-11-09 | Kao Corp | 経皮吸収促進剤およびこれを含有する外用剤 |
GB8723846D0 (en) * | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
GB9020544D0 (en) * | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
EP0566135A1 (en) * | 1992-04-17 | 1993-10-20 | Takeda Chemical Industries, Ltd. | Transmucosal composition comprising a peptide and a cytidine derivative |
US5346701A (en) * | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US6019988A (en) * | 1996-11-18 | 2000-02-01 | Bristol-Myers Squibb Company | Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage |
IT1291362B1 (it) * | 1997-05-13 | 1999-01-07 | Vectorpharma Int | Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi |
US6416779B1 (en) * | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
US5985313A (en) | 1997-10-22 | 1999-11-16 | New York Blood Center, Inc. | Method for decreasing the frequency of transmission of viral infections using cellulose acetate phthalate or hydroxypropyl methylcellulose phthalate excipients |
US6143278A (en) | 1998-02-23 | 2000-11-07 | Elkhoury; George F. | Topical application of opioid analgesic drugs such as morphine |
US6103266A (en) * | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
US7622117B2 (en) * | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
-
2003
- 2003-05-22 EP EP03729092A patent/EP1509209A1/en not_active Withdrawn
- 2003-05-22 CN CNB038147270A patent/CN100522245C/zh not_active Expired - Fee Related
- 2003-05-22 US US10/444,634 patent/US7939098B2/en not_active Expired - Fee Related
- 2003-05-22 JP JP2004506788A patent/JP2005531570A/ja active Pending
- 2003-05-22 BR BR0311530-5A patent/BR0311530A/pt not_active Application Discontinuation
- 2003-05-22 WO PCT/US2003/016313 patent/WO2003099264A1/en active Application Filing
- 2003-05-22 AU AU2003233653A patent/AU2003233653B2/en not_active Expired - Fee Related
- 2003-05-22 MX MXPA04011584A patent/MXPA04011584A/es not_active Application Discontinuation
- 2003-05-22 CA CA002486909A patent/CA2486909A1/en not_active Abandoned
-
2004
- 2004-11-25 NO NO20045140A patent/NO20045140L/no not_active Application Discontinuation
-
2006
- 2006-02-16 HK HK06102039.3A patent/HK1081844A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR0311530A (pt) | 2005-05-10 |
AU2003233653A1 (en) | 2003-12-12 |
HK1081844A1 (en) | 2006-05-26 |
JP2005531570A (ja) | 2005-10-20 |
AU2003233653B2 (en) | 2008-08-07 |
MXPA04011584A (es) | 2005-03-31 |
US7939098B2 (en) | 2011-05-10 |
US20030219472A1 (en) | 2003-11-27 |
EP1509209A1 (en) | 2005-03-02 |
CN100522245C (zh) | 2009-08-05 |
CN1662228A (zh) | 2005-08-31 |
CA2486909A1 (en) | 2003-12-04 |
WO2003099264A1 (en) | 2003-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20045140L (no) | Blandinger og fremgangsmate for transmukosal legemiddelavlevering og kryobeskyttelse | |
AU725283B2 (en) | Bioadhesive pharmaceutical composition for the controlled release of active principles | |
ES2270335T3 (es) | Composicion farmaceutica de efecto rapido. | |
DE602004017127D1 (de) | Langandauernde, aromatisierte darreichungsform zur verlängerten freisetzung von aktivstoffen im mund | |
DE60312523D1 (de) | Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit | |
DE69916486D1 (de) | Nicotin enthaltende pharmazeutische zusammensetzungen mit schneller transmukosaler absorption | |
WO2006044421A3 (en) | Cardiac safe, rapid medication delivery | |
AR033444A1 (es) | Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla | |
ATE347879T1 (de) | Transdermale pharmazeutische zusammensetzung zur wirkstoffverabreichung | |
IL190838A0 (en) | Intranasal administration of rapid acting insulin | |
WO2007125545A3 (en) | Transmucosal composition | |
BRPI0315315B8 (zh) | ||
DE602005014962D1 (de) | Insulinzusammensetzungen mit verbesserter wirkstoffabsorption | |
NO20051463L (no) | Inhaleringssammensetninger med hoy legemiddelandel | |
UA92011C2 (ru) | Облатка, содержащая стероидные гормоны | |
US8722744B2 (en) | Galenical form for the administration of paracetamol by transmucous means | |
JP2019514990A5 (zh) | ||
WO2004034962A3 (en) | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome | |
Rasool et al. | In vitro evaluation of miconazole mucoadhesive buccal films | |
WO2005010022A3 (en) | Agonist polypeptide of receptor for zot and zonulin | |
AR043370A1 (es) | Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga | |
DE60316714D1 (de) | Pharmazeutische formulierung enthaltend olanzapin | |
JO2492B1 (en) | A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients | |
Akhter et al. | Comprehensive review on buccal drug delivery systems | |
AR050937A1 (es) | Composicion para administracion a traves de la mucosa y metodo para aumentar la absorcion a traves de la mucosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |